Sector specialism is essential for clinical labeling solutions

PRISYM ID’s Chief Executive Richard Adams has said that to meet the unique labeling and product information needs of the life science industry it has never been more important for regulated labeling technology companies to draw on deep, specialized knowledge and experience of the sector to enable it to continue to deliver the unmatched standards that patient safety and outcome demand.

Setting out his ambitions for 2021, Mr. Adams said that there were important opportunities for clinical research and medical devices companies to build on the ingenuity applied throughout supply chains in response to COVID-19 – and that the unique complexities and challenges involved meant that he would continue to focus the company’s efforts squarely on supporting the life science and medical device sectors to deliver the specialized knowledge and solutions they value most.

It comes as PRISYM ID announces five new business wins for the start of 2021, with new accounts spanning clinical trials, pharmaceutical and medical device sectors and with significant growth of the company’s flagship PRISYM 360 platform in the Cloud. Mr. Adams believes this positive start to the year is a sign that life science and medical device companies are looking for expert partners who understand the operational and regulatory challenges facing them and can deliver scalable solutions that meet their unique requirements.

“It is clear to me that the pandemic will leave a lasting legacy for the life science industry. It has fundamentally re-written the rules in terms of what we now think is feasible in terms of speed-to-market of new products and has probably raised expectations considerably.

“The challenge now is to lock in these gains. I’m conscious that PRISYM ID has learnt so much working with our clients in this environment, and I want to make sure we maintain a laser-like focus on both the medical device and life sciences sectors as we help them reconfigure after COVID.

“From my perspective, specialization is a key part of this: it’s never been more important for supply chain partners to understand the terrain, know the challenges and be able to operate as intelligent business partners to pharma, CROs and med tech firms as they negotiate their way forward in 2021. We have to listen even harder to understand how companies visualize their operating practices going forward but the great news is, I know PRISYM ID is positioned better than anyone to respond and deliver the regulated labeling and content management solutions they need.

“Above all else, being a life science and medical device sector specialist is our passion and core purpose at PRISYM ID – it’s really important to me and the whole team that this remains our singular focus, and I think these new business wins show that it’s also a very powerful proposition for the market.”

Mr. Adams leadership approach focusses the company to collaborate with customers and users, to understand the pressures they face as they develop, market and ship products, whilst regulatory demands change. He sees this as a key differentiator to make sure the PRISYM ID technology and expertise is continually focused on helping customers to reduce risk, deliver efficiencies, and ensure compliance.